In an evolving regulatory landscape, traditional approaches to pharmaceutical compliance may not be sufficient to mitigate risks effectively. One expert believes that a behavioral approach may provide fresh insights.
In a recent podcast, Scott Young, Principal Advisor and Head of the Private Sector at Behavior Insights Team, Americas, talked about the importance of understanding how people make decisions to enhance the effectiveness of compliance teams.
Young posits that compliance is not just about understanding laws, but rather about influencing human behavior and guiding people towards making the right decisions. The integral role of behavioral science is emphasized in his discussion.
Behavioral science sheds light on why individuals act the way they do, enabling compliance teams to develop strategies that can effectively alter these behaviors in a manner that supports compliance. Young advocates for this particular approach because it provides a broader perspective on how to think about human conduct and consequently, how to manage it within the confines of law.
This approach can prove critical for legal professionals working within leading corporations and law firms amidst the complex regulatory frameworks they often operate under. It is an alternative worth considering for those looking for novel ways to improve their compliance programs and align them more closely with human behavior.
Consequently, the ultimate goal of a behavioral approach to compliance is not just to merely react to breaches when they occur, which has traditionally been the case, but to act proactively by understanding and influencing the behavior that leads to those breaches in the first place.
In a nutshell, this perspective represents not just a shift in how compliance teams operate, but more importantly, a shift in how they think – suggesting that both the understanding and the influencing of human behavior can be the game-changer for more effective compliance.